Pasar al contenido principal

EL INTERACTOMA DE MEMBRANA DE LAS PROTEINAS DE LA FAMILIA BCL-2 COMO DIANA ANTITUMORAL

PID2020-115048RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIÓN DE LA COMUNIDAD VALENCIANA CENTRO DE INVESTIGACION PRÍNCIPE FELIPE

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Engineering nanoparticle communication in living systems by stigmergy: An application to enhance antitumor therapy in triple-negative breast cancer

  • Estepa-Fernández, Alejandra
  • Lérida-Viso, Araceli
  • Blandez, Juan F.
  • Alfonso-Navarro, María
  • Vivo-Llorca, Gema
  • Orzaez, Mar
  • García-Fernández, Alba|||0000-0002-8416-1674
  • Morella-Aucejo, Ángela|||0000-0002-6357-949X
  • Esteve-Moreno, Juan José|||0000-0002-1259-7663
  • Candela-Noguera, Vicente
  • Sancenón Galarza, Félix|||0000-0002-5205-7135
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] The engineering of nanoparticle communication has gained growing attention in the last years, however, efforts to communicate nanoparticles with living systems is still a barely studied emerging topic. Here, we explore a nanoparticle cooperation strategy that involves nanoparticle-cell-nanoparticle communication in vivo through stigmergy (a strategy in which nanodevices communicate by modifying the environment). First, mesoporous silica nanoparticles loaded with the senescence inductor palbociclib and coated with a heterobifunctional poly(ethylene glycol) that binds covalently to a MUC1-binding aptamer (NP(palbo)PEG-MUC1), is designed to specifically deliver the pro-senescent drug palbociclib in MDA-MB-231 breast cancer cells. Once the first nanoparticle modifies the environment due to the induction of senescence, a second community of nanoparticles, loaded with the senolytic navitoclax and coated with a hexa-oligo-saccharide (NP(nav)-Gal), releases its cargo to eliminate tumor senescent cells selectively. The targeted therapy through stigmergy communication is tested in vitro, and in vivo, where delays tumor growth and reduces metastases in a mouse model of human triple-negative breast cancer while minimizing undesired drugs side effects., R.M. laboratory members thank the financial support from the Spanish Government projects RTI2018-100910-B-C41 and RTI2018-101599-B-C22 and (MCUI/FEDER, EU) and the Generalitat Valenciana (project PROMETEO 2018/024). This work was funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Research Council. Neither the European Union nor the granting authority can be held responsible for them. This work was supported by the European Research Council (ERC) via Advanced Grant (101052997, EDISON). M.O. thanks the financial support from the Spanish Government project (PID2020-115048RB-I0 0) and the Generalitat Valenciana (project PROMETEO/2019/065). A.E-F. is grateful to the Spanish Government for her Ph.D. grant (FPU17/05454), A.L-V. is grateful to the Instituto de Salud Carlos III for her Ph.D. i-PFIS grant (IFI17/00039). J.B. thanks to the Instituto de Salud Carlos III for his Sara Borrell contract (CD19/00038).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Pharmacological senolysis reduces doxorubicin-induced cardiotoxicity and improves cardiac function in mice

  • Lerida-Viso, Araceli
  • Estepa-Fernández, Alejandra
  • Lozano-Torres, Beatriz
  • Alfonso, María
  • Blandez, Juan F.
  • Bisbal, Viviana
  • Sepúlveda, Pilar
  • Orzáez, Mar
  • Morella-Aucejo, Ángela|||0000-0002-6357-949X
  • García-Fernández, Alba|||0000-0002-8416-1674
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Many anticancer agents used in clinics induce premature senescence in healthy tissues generating accelerated aging processes and adverse side-effects in patients. Cardiotoxicity is a well-known limiting factor of anticancer treatment with doxorubicin (DOX), a very effective anthracycline widely used as antitumoral therapy in clinical practice, that leads to long-term morbidity and mortality. DOX exposure severely affects the population of cardiac cells in both mice and human hearts by inducing premature senescence, which may represent the molecular basis of DOX-induced cardiomyopathy. Here, we demonstrate that senescence induction in the heart contributes to impaired cardiac function in mice upon DOX treatment. Concomitant elimination of senescent cells with the senolytic Navitoclax in different formulations produces a significant decrease in senescence and cardiotoxicity markers together with the restoration of the cardiac function in mice followed by echocardiography. These results evidence the potential clinical use of senolytic therapies to alleviate cardiotoxicities induced in chemotherapy-treated patients., R.M. laboratory members thank the financial support from the Spanish Government projects RTI2018-100910-B-C41 and RTI2018-101599-B-C22 (MCUI/FEDER, EU)) and the Generalitat Valenciana (project PROMETEO 2018/024). M.O. thanks the financial support from the Spanish Government project (PID2020-115048RB-I00) and the Generalitat Valenciana (project PROMETEO/2019/065). A. L-V. is grateful to the Instituto de Salud Carlos III for her Ph.D. i-PFIS grant (IFI17/00039). A.E-F. and B.L.-T thanks to the Spanish Government for their Ph.D. grant (FPU17/05454) and (FPU15/02707). J.B. thanks to the Instituto de Salud Carlos III for his Sara Borrell contract (CD19/00038). M.A. thanks her postdoctoral fellowship (PAID-10-17). The funders had no role in the design, data collection, decision to publish, or preparation of the manuscript. The authors thank Alberto Hernandez for confocal microscopy, Alicia Martinez for flow cytometry, and Laura Ramirez for genomics guidance. The authors thank for the use of Biorender.com.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Targeted Delivery of the Pan-Inflammasome Inhibitor MM01 as an Alternative Approach to Acute Lung Injury Therapy

  • García-Fernández, Alba|||0000-0002-8416-1674
  • Garrido-García, Eva María
  • Sancenón Galarza, Félix|||0000-0002-5205-7135
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Sancho, Mónica
  • Bisbal, Viviana
  • Orzáez, Mar
[EN] Acute lung injury (ALI) is a severe pulmonary disorder responsible for high percentage of mortality and morbidity in intensive care unit patients. Current treatments are ineffective, so the development of efficient and specific therapies is an unmet medical need. The activation of NLPR3 inflammasome during ALI produces the release of proinflammatory factors and pyroptosis, a proinflammatory form of cell death that contributes to lung damage spreading. Herein, it is demonstrated that modulating inflammasome activation through inhibition of ASC oligomerization by the recently described MM01 compound can be an alternative pharmacotherapy against ALI. Besides, the added efficacy of using a drug delivery nanosystem designed to target the inflamed lungs is determined. The MM01 drug is incorporated into mesoporous silica nanoparticles capped with a peptide (TNFR-MM01-MSNs) to target tumor necrosis factor receptor-1 (TNFR-1) to proinflammatory macrophages. The prepared nanoparticles can deliver the cargo in a controlled manner after the preferential uptake by proinflammatory macrophages and exhibit anti-inflammatory activity. Finally, the therapeutic effect of MM01 free or nanoparticulated to inhibit inflammatory response and lung injury is successfully demonstrated in lipopolysaccharide-mouse model of ALI. The results suggest the potential of pan-inflammasome inhibitors as candidates for ALI therapy and the use of nanoparticles for targeted lung delivery., This research was supported by Project Nos. PID2021-126304OB-C41, PID2021-128141OB-C22, and PID2020-115048RB-I00 funded by MCIN/AEI/10.13039/501100011033 and by European Regional Development Fund - A way of doing Europe. The authors also thank Generalitat Valenciana (PROMETEO Project CIPROM/2021/007 and PROMETEO 2019/065) for support. E.G. is grateful to the Spanish MIU and European Union-Next Generation EU for her "Margarita Salas" postdoctoral grant (UP2021-036). The authors would also like to thank Animal Facilities from Centro de Investigacion Principe Felipe for its support in the animal research and procedures, and I. Borred and J. Forteza from Instituto Valenciano de Patologia for its technical support in the histopathology analysis. The authors thank for the use of Biorender.com in the figures and graphical abstract.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Combination of palbociclib with navitoclax based-therapies enhances in vivo antitumoral activity in triple-negative breast cancer

  • Estepa-Fernández, Alejandra
  • Lerida-Viso, Araceli
  • Blandez, Juan F.
  • Galiana, Irene
  • Orzaez, Mar
  • García-Fernández, Alba|||0000-0002-8416-1674
  • Sancenón Galarza, Félix|||0000-0002-5205-7135
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Triple-negative breast cancer (TNBC) is a very aggressive subtype of breast cancer with a poor prognosis and limited effective therapeutic options. Induction of senescence, arrest of cell proliferation, has been explored as an effective method to limit tumor progression in metastatic breast cancer. However, relapses occur in some patients, possibly as a result of the accumulation of senescent tumor cells in the body after treatment, which promote metastasis. In this study, we explored the combination of senescence induction and the subsequent removal of senescent cells (senolysis) as an alternative approach to improve outcomes in TNBC patients. We demonstrate that a combination treatment, using the senescence-inducer palbociclib and the senolytic agent navitoclax, delays tumor growth and reduces metastases in a mouse xenograft model of aggressive human TNBC (hTNBC). Furthermore, considering the off-target effects and toxicity derived from the use of navitoclax, we propose a strategy aimed at minimizing the associated side effects. We use a galacto-conjugated navitoclax (nav-Gal) as a senolytic prodrug that can preferentially be activated by ß-galactosidase overexpressed in senescent cells. Concomitant treatment with palbociclib and nav-Gal in vivo results in the eradication of senescent hTNBC cells with consequent reduction of tumor growth, while reducing the cytotoxicity of navitoclax. Taken together, our results support the efficacy of combination therapy of senescence-induction with senolysis for hTNBC, as well as the development of a targeted approach as an effective and safer therapeutic opportunity, This work was supported by the Spanish Government projects (RTI2018-100910-B-C41, RTI2018-101599-B-C22 and PID2020 -115048RB-I00 (MCUI/FEDER, EU) ) and the Generalitat Valenciana (PROMETEO 2018/024 and PROMETEO/2019/065) . A.E-F. is grateful to the Spanish Government for her Ph.D. grant (FPU17/05454) , A.L-V. is grateful to the Instituto de Salud Carlos III for her Ph.D. i-PFIS grant (IFI17/00039) . J.B. thanks to the Instituto de Salud Carlos III for his Sara Borrell contract (CD19/00038) . Thank the financial support from the FEDER found of European Union (IDIFEDER/2021/044) . The authors thank Alberto Herna?ndez for the confocal microscope, Alicia Martinez for flow cytometry, and Viviana Bisbal for veterinary assistance. The authors thank for the use of Biorender.com in the graphical abstract Fig. 2 and Fig. 3.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Modulation of mitochondria–endoplasmic reticulum contacts (MERCs) by small molecules as a new strategy for restoring lipid metabolism in an amyotrophic lateral sclerosis model

  • Etxebeste-Mitxeltorena, Mikel
  • Flores-Romero, Héctor
  • Ramos-Inza, Sara
  • Masiá, Esther
  • Nenchova, Maria
  • Montesinos, Jorge
  • Martínez-González, Loreto
  • Porras, Gracia
  • Orzáez, Mar
  • Vicent, María J.
  • Gil, Carmen
  • Area-Gomez, Estela
  • García-Sáez, Ana J.
  • Martínez Gil, Ana
16 p.-15 fig.-3 tab.1 graph. abst., Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease without effective treatment. The progressive motoneuron death in ALS is associated with alterations in lipid metabolism. As its regulation occurs in mitochondria-associated endoplasmic reticulum (ER) membranes (MAMs), modulation of mitochondria-ER contacts (MERCs) is emerging as a crucial factor in MAM formation and lipid metabolism control. Using the MERLIN biosensor in a high-throughput screening within the EU-OPENSCREEN ERIC, we discovered small molecules that increase MERCs in HCT116 cells, enhancing their ability to uptake cholesterol. We demonstrated that cholesterol trafficking is decreased in an ALS patient-derived cell model, and this trafficking is restored after treatment with the discovered MERC modulator 24. Electron microscopy revealed that treatment with compound 24 increases MERCs, promotes lipid droplet formation, and restores mitochondrial cristae. Overall, the brain-permeable MERC modulator, compound 24, may serve as a valuable pharmacological tool for studying MAM function and holds potential for in vivo studies in ALS and other MAM dysfunction diseases., This research was funded by European Commission Horizon 2020 Framework Programme (Project EU-OPENSCREEN-DRIVE - GA 823893), La Caixa and Luzón Foundation (grant no. HR21-00931), Luzón Foundation (UNZUE project), MCIN/AEI/10.13039/501100011033 (grant no. PID2019-105600RB-I00 to A.M., PID2019-108806RB-I00 to M.J.V., PID2020-115048RB-I00 to M.O., and PID2022-141616OA-I00 to H.F.-R.), Consejo Superior de Investigaciones Cientificas PTI+ Neuroaging (European Union Next Generation EU/PRTR), Spanish Health Institute Carlos III (grant no. CB18/05/00040 to A.M., and CB22/12/00048 to M.J.V.), and Deutsche Forschungsgemeinschaft. (grant CRC1403 to A.-J.G.-S. and CRC1218 advanced postdoctoral grant to H.F.-R.). Finally, A.-J.G.-S. thanks to the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement no. 817758); and H.F.-R. acknowledges support by the Ikerbasque Basque Foundation for Science, COFUND, H2020-MSCA-COFUND-2020-101034228-WOLFRAM2, and by ERDF a way of making Europe (ERDF/EU)., Peer reviewed